Paolo Tarantino: SHR-A1811 x8 +/- pyrotinib vs TCHP for stage III HER2+ early breast cancer
Paolo Tarantino shared on X:
“Impressive results from a randomized trial of neoadjuvant SHR-A1811 x8 (aka T-DXd cousin) +/- pyrotinib vs TCHP for mostly stage III HER2+ eBC. Comparable pCR rates across arms. Bodes well for DB11, though key differences in the dose and trial design may have relevant impact.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023